WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, December 20, 2007

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ	
☐	L10	L8 and ferm bp-8432	1
☐	L9	L8 and ferm bp-8431	1
☐	L8	L7 and hybridoma	9
☐	L7	L6 and antibody	29
☐	L6	zaq ligand-2 or zaql-2 or zaql or bv8 maturation peptide or prokinectin-2 or pk-2	87
		DB=USPT,PGPB; PLUR=YES; OP=ADJ	
☐	L5	MASUDA-YASUSHI!	47
☐	L4	MASUDA-YASUSHI!	47
☐	L3	NOGUCHI-JIRO!	4
☐	L2	NOGUCHI-JIRO!	4
☐	L1	MATSUMOTO-HIROKAZU!	33

END OF SEARCH HISTORY

Case # 10/576066
WEST
AD
12/20/07

FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 18:15:51 ON 20 DEC 2007

FILE 'BIOSIS' ENTERED AT 18:15:51 ON 20 DEC 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 18:15:51 ON 20 DEC 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 18:15:51 ON 20 DEC 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'DISSABS' ENTERED AT 18:15:51 ON 20 DEC 2007
COPYRIGHT (C) 2007 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'BIOTECHNO' ENTERED AT 18:15:51 ON 20 DEC 2007
COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s zaq ligand-2 or zaql-2 or zaql or bv8 maturation or prokinectin-2 or pk-2
L1 734 ZAQ LIGAND-2 OR ZAQL-2 OR ZAQL OR BV8 MATURATION OR PROKINECTIN-2 OR PK-2

=> s l1 and antibody
L2 10 L1 AND ANTIBODY

=> s l2 and hybridoma
L3 0 L2 AND HYBRIDOMA

=> s l2 and py<2004
1 FILES SEARCHED...
5 FILES SEARCHED...
L4 7 L2 AND PY<2004

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5 4 DUP REM L4 (3 DUPLICATES REMOVED)

=> disp l5 ibib abs 1-4

L5 ANSWER 1 OF 4 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2000261967 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10799473
TITLE: Monoclonal antibody differentiation of Mycoplasma mycoides subsp. mycoides small-colony strains causing contagious bovine pleuropneumonia from less important large-colony strains.
AUTHOR: Rurangirwa F R; Shompole P S; Wambugu A N; McGuire T C
CORPORATE SOURCE: Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, Washington 99164-7040, USA.. ruvuna@vetmed.wsu.edu
SOURCE: Clinical and diagnostic laboratory immunology, (2000 May) Vol. 7, No. 3, pp. 519-21.
Journal code: 9421292. ISSN: 1071-412X.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200006
ENTRY DATE: Entered STN: 6 Jul 2000
Last Updated on STN: 6 Jul 2000
Entered Medline: 27 Jun 2000

Case #10/576066
STN AB
12/20/07

AB Monoclonal antibody (MAb) PK-2 inhibited the in vitro growth of nine Mycoplasma mycoides subsp. mycoides small-colony strains. In contrast to the results with polyclonal antisera, growth inhibition by MAb PK-2 was specific for M. mycoides subsp. mycoides small-colony strains and constituted a reliable means of distinguishing them from other mycoplasmas.

L5 ANSWER 2 OF 4 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1993081850 EMBASE
TITLE: Detection of subtle differences in the surface structure of lysozymes by use of an immobilized Fab fragment.
AUTHOR: Ueda T.; Abe Y.; Akasaki K.; Yamaguchi Y.; Tsuji H.; Kawano K.; Yamada H.; Imoto T.
CORPORATE SOURCE: T. Imoto, Faculty of Pharmaceutical Sciences, Kyushu University, 62, Maidashi, Higashi-ku, Fukuoka 812, Japan
SOURCE: Journal of Biochemistry, (1993) Vol. 113, No. 2, pp. 174-179.
ISSN: 0021-924X CODEN: JOBIAO
COUNTRY: Japan
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 029 Clinical and Experimental Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 18 Apr 1993
Last Updated on STN: 18 Apr 1993

AB A method was developed to evaluate the association constant at physiological pH (pH 7.5) between a lysozyme and the Fab fragment derived from anti-lysozyme monoclonal antibody 37-7, which was immobilized to the adsorbent for HPLC. Comparison of the association constants between lysozymes and the immobilized Fab fragment indicated that mAb 37-7 recognized the prominently exposed regions (hills and ridges) around His15 of hen lysozyme, but His15 itself was not directly involved in the binding with mAb 37-7. Moreover, the epitope was confirmed by the reactivity of His15 with monoiodoacetic acid in the presence of mAb 37-7. The association constant of 15-carboxymethylated histidine lysozyme 15CM lysozyme) with the immobilized Fab fragment was smaller by one-seventh than that of 15-carboxamidated histidine lysozyme, though the side chains introduced were almost identical in size. From the pH titration of 15CM lysozyme with (13)C-enriched carboxyl group by use of (13)C-NMR, the pK(2) of the introduced carboxyl group was evaluated to be 5.06. Since the carboxyl group was fully ionized under the conditions of measurement (pH 7.5 electrostatic repulsion was found to disturb severely the association between mAb 37-7 and hen lysozyme. Moreover, it was demonstrated that, because of the high reproducibility of measurement, the immobilized Fab fragment could detect subtle differences in the surface structure of lysozymes.

L5 ANSWER 3 OF 4 MEDLINE on STN

ACCESSION NUMBER: 84134401 MEDLINE
DOCUMENT NUMBER: PubMed ID: 6321348
TITLE: Toxoids of Pseudomonas aeruginosa exotoxin-A: photoaffinity inactivation of purified toxin and purified toxin derivatives.
AUTHOR: Callahan L T 3rd; Martinez D; Marburg S; Tolman R L; Galloway D R
SOURCE: Infection and immunity, (1984 Mar) Vol. 43, No. 3, pp. 1019-26.
Journal code: 0246127. ISSN: 0019-9567.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198404

ENTRY DATE: Entered STN: 19 Mar 1990
Last Updated on STN: 20 Apr 2002
Entered Medline: 24 Apr 1984

AB For the preparation of greatly detoxified but highly immunogenic toxoids, two enzymatically active, low-toxicity derivatives of Pseudomonas aeruginosa exotoxin-A were further inactivated by photoaffinity labeling. These derivatives were formed during toxin purification, when a relatively crude toxin preparation was concentrated by ammonium sulfate precipitation and subsequently dialyzed. These derivatives, designated peak-1 protein (PK-1) and peak-2 protein (PK-2) were antigenically indistinguishable from native toxin, but had isoelectric points (5.00 and 4.90, respectively) that were different from that of the native toxin (4.95). Although the enzymatic activities and molecular weights of PK-1 and PK-2 were similar to those of native toxin, their toxicities were greatly reduced (ca. 500-fold). Photoaffinity labeling of fully active toxin-A, purified by a process which limits the formation of these derivatives, decreased its enzymatic activity (ca. 30-fold) and toxicity (ca. 100-fold). Likewise, photoaffinity labeling of purified PK-1 and PK-2 decreased their enzymatic activities and toxicities (ca. 30-fold and 100-fold, respectively) and, thus, yielded toxoids that were ca. 50,000-fold less toxic than unpurified native toxin. These toxoids were irreversibly detoxified and highly immunogenic during 9 months of storage at 4 degrees C.

L5 ANSWER 4 OF 4 EMBASE

ACCESSION NUMBER: 1983021678 EMBASE
TITLE: The role of pili in the adhesion of Escherichia coli to human urinary tract epithelial cells.
AUTHOR: Korhonen T.K.; Vaisanen V.; Kallio P.; et. al.
CORPORATE SOURCE: Dep. Gen. Microbiol., Univ. Helsinki, Finland
SOURCE: Scandinavian Journal of Infectious Diseases, (1982) Vol. 14, No. Suppl.33, pp. 26-31.
ISSN: 0036-5548 CODEN: SJIDB7
COUNTRY: Sweden
DOCUMENT TYPE: Journal
FILE SEGMENT: 028 Urology and Nephrology
004 Microbiology: Bacteriology, Mycology, Parasitology and Virology
LANGUAGE: English
ENTRY DATE: Entered STN: 9 Dec 1991
Last Updated on STN: 9 Dec 1991

AB Pili or fimbriae were purified by a new technique involving solubilization from the bacterial outer membrane by deoxycholate and separation from flagella by 6M urea. This technique was employed to clarify the role of pili for the adherence of urinary tract pathogenic E. coli; a virulence factor in urinary tract infection. The isolated pili formed single bands in SDS gels and were pure by serologic criteria. They retained the binding properties of the whole pillated bacteria, since they bound to uroepithelial cells and agglutinated erythrocytes. Antibodies to purified pili blocked adhesion. The adhesion and hemagglutination reactions by the strains used for pilus purification were mannose-resistant but globotetraos-sensitive, i.e. the strains recognized globoseries glycolipid receptors in the target cells. The occurrence of this property in a freshly collected material of strains was tested using erythrocytes of blood groups P(1), Pk (2) and p.

=>

FILE 'CAPLUS' ENTERED AT 17:57:43 ON 20 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Dec 2007 VOL 147 ISS 26
FILE LAST UPDATED: 19 Dec 2007 (20071219/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s bv8 maturation peptide or zaq ligand-2 or zaql-2 or zaql or prokinectin-2 or pk-2

```
          65 BV8
       77119 MATURATION
          92 MATURATIONS
       77155 MATURATION
                (MATURATION OR MATURATIONS)
      385023 PEPTIDE
      280400 PEPTIDES
      491262 PEPTIDE
                (PEPTIDE OR PEPTIDES)
           0 BV8 MATURATION PEPTIDE
                (BV8(W)MATURATION(W)PEPTIDE)
          15 ZAQ
      333972 LIGAND
      227288 LIGANDS
      454416 LIGAND
                (LIGAND OR LIGANDS)
     9415890 2
           0 ZAQ LIGAND-2
                (ZAQ(W)LIGAND(W)2)
           2 ZAQL
     9415890 2
           1 ZAQL-2
                (ZAQL(W)2)
           2 ZAQL
           0 PROKINECTIN
     9415890 2
           0 PROKINECTIN-2
                (PROKINECTIN(W)2)
       25075 PK
        2495 PKS
       27262 PK
                (PK OR PKS)
     9415890 2
         431 PK-2
                (PK(W)2)
L1       433 BV8 MATURATION PEPTIDE OR ZAQ LIGAND-2 OR ZAQL-2 OR ZAQL OR PROK
             INECTIN-2 OR PK-2
```

```
=> s l1 and antibody
        321652 ANTIBODY
        383695 ANTIBODIES
        509547 ANTIBODY
                  (ANTIBODY OR ANTIBODIES)
L2            6 L1 AND ANTIBODY

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3            6 DUP REM L2 (0 DUPLICATES REMOVED)

=> s l3 and py<2004
L4            6 S L3
      23975090 PY<2004
L5            3 L4 AND PY<2004

=> disp l5 ibib abs 1-3

L5   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2001:472401  CAPLUS
DOCUMENT NUMBER:          135:74133
TITLE:                    Protein kinase stress-related proteins (PKSRP) of
                          Physcomitrella and their use in improving plant
                          tolerance to environmental stress
INVENTOR(S):              Da Costa e Silva, Oswaldo; Ishitani, Manaub; Henkes,
                          Stefan; Van Thielen, Nocha; Chen, Ruoying
PATENT ASSIGNEE(S):       Basf Plant Science G.m.b.H., Germany
SOURCE:                   PCT Int. Appl., 86 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   4
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2001045492         A2    20010628    WO 2000-US34970          20001222 <--
     WO 2001045492         A3    20020801
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 200127340          A     20010703    AU 2001-27340            20001222 <--
     EP 1251731            A2    20021030    EP 2000-990296           20001222 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     AT 324780             T     20060615    AT 2000-993487           20001222
     ES 2258489            T3    20060901    ES 2000-993487           20001222
     AT 357135             T     20070415    AT 2000-990297           20001222
     EP 1797754            A1    20070620    EP 2007-2748             20001222
         R:  AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
             NL, PT, SE, TR, AL, LT, LV, MK, RO, SI
     ES 2279777            T3    20070901    ES 2000-990297           20001222
     US 2003217392         A1    20031120    US 2002-168844           20021118 <--
     US 7223903            B2    20070529
     US 2007261131         A1    20071108    US 2007-621688           20070110
PRIORITY APPLN. INFO.:                       US 1999-171745P      P   19991222
                                             EP 2000-990297       A3  20001222
```

WO 2000-US34970 W 20001222
US 2002-168844 A3 20021118

AB A transgenic plant transformed by a protein kinase stress-related protein (PKSRP) coding nucleic acid, wherein expression of the nucleic acid sequence in the plan results in increased tolerance to environmental stress as compared to a wild type variety of the plant. This invention describes three PKSRP, PK-1, PK-2 and MAP-3 from arabidopsis. Also provided are agricultural products, including seeds, produced by the transgenic plants. Also provided are isolated PKSRP, and isolated nucleic acid coding PKSRP, and vectors and host cells containing the latter. Further provided are methods of producing transgenic plants expressing PKSRP, and methods of identifying novel PKSRP and methods of modifying the expression of PKSRP in plants.

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:371127 CAPLUS
DOCUMENT NUMBER: 134:28342
TITLE: Monoclonal antibody differentiation of Mycoplasma mycoides subsp. mycoides small-colony strains causing contagious bovine pleuropneumonia from less important large-colony strains
AUTHOR(S): Rurangirwa, Fred R.; Shompole, Patrick S.; Wambugu, Anderson N.; Mcguire, Travis C.
CORPORATE SOURCE: Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA, 99164-7040, USA
SOURCE: Clinical and Diagnostic Laboratory Immunology (2000), 7(3), 519-521
CODEN: CDIMEN; ISSN: 1071-412X
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Monoclonal antibody (MAb) PK-2 inhibited the in vitro growth of nine Mycoplasma mycoides subsp. mycoides small-colony strains. In contrast to the results with polyclonal antisera, growth inhibition by MAb PK-2 was specific for M. mycoides subsp. mycoides small-colony strains and constituted a reliable means of distinguishing them from other mycoplasmas.
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:604486 CAPLUS
DOCUMENT NUMBER: 115:204486
TITLE: Differences in phorbol ester-induced decrease of the activity of protein kinase C isozymes in rat hepatocytes
AUTHOR(S): Robles-Flores, Martha; Alcantara-Hernandez, Rocio; Garcia-Sainz, J. Adolfo
CORPORATE SOURCE: Inst. Fisiol. Cel., Univ. Nac. Auton. Mexico, Mexico City, 04510, Mex.
SOURCE: Biochimica et Biophysica Acta, Molecular Cell Research (1991), 1094(1), 77-84
CODEN: BBAMCO; ISSN: 0167-4889
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Two main forms of protein kinase C (PKC) activity were found in rat hepatocytes using DEAE-cellulose chromatog.: PK 1 and PK 2. Treatment of cells with 1 μM TPA for 15 min caused a marked loss of PKC 1 activity and only a small loss of PKC 2 activity. Hydroxyapatite column chromatog. resolved PKC 1 into 3 distinct peaks 1a, 1b, and 1c, and PKC 2 into 4 peaks 2a, 2b, 2c, and 2d. Immunoblot anal. with isoenzyme-specific monoclonal antibodies identified peak 1a as PKC-β and peak 1b as PKC-α; the other peaks of activity were

not identified. Treatment with TPA provoked a loss of activity of peaks 1b (PKC-α) and 1c, whereas peak 1a (PKC-β) activity was not affected. The peaks of activity corresponding to PCK 2 did not show any major change due to TPA treatment except peak 2d that decreased. The apparent disappearance of PKC histone kinase activity induced by TPA was also observed using other substrates (protamine or vinculin). The TPA-induced decrease in activity occurs in a time-dependent and dose-dependent fashion. However, the time courses, the extent of depletion, and the potency order of phorbol esters in induction of an activity decrease in the 2 groups of isoforms exhibited substantial differences.

```
=> E MASUDA YASUSHI/IN 25
E1            9      MASUDA YASUNOBU/IN
E2           76      MASUDA YASUO/IN
E3           38 --> MASUDA YASUSHI/IN
E4            1      MASUDA YASUSUKE/IN
E5            1      MASUDA YASUTAKA/IN
E6            2      MASUDA YASUTARO/IN
E7            7      MASUDA YASUTO/IN
E8            6      MASUDA YASUTOSHI/IN
E9            2      MASUDA YASUTSUGU/IN
E10           7      MASUDA YASUYUKI/IN
E11           1      MASUDA YOGORO/IN
E12          10      MASUDA YOICHI/IN
E13           8      MASUDA YOICHIRO/IN
E14          41      MASUDA YOJI/IN
E15           3      MASUDA YOKO/IN
E16           1      MASUDA YORIKO/IN
E17          37      MASUDA YOSHIAKI/IN
E18           2      MASUDA YOSHIE/IN
E19          18      MASUDA YOSHIFUMI/IN
E20           1      MASUDA YOSHIHARU/IN
E21           9      MASUDA YOSHIHIDE/IN
E22          46      MASUDA YOSHIHIKO/IN
E23           1      MASUDA YOSHIHIRA/IN
E24          50      MASUDA YOSHIHIRO/IN
E25           5      MASUDA YOSHIHISA/IN

=> S (E3) AND (ANTIBODY)
             38 "MASUDA YASUSHI"/IN
         321652 ANTIBODY
         383695 ANTIBODIES
         509547 ANTIBODY
                  (ANTIBODY OR ANTIBODIES)
L6            7 ("MASUDA YASUSHI"/IN) AND (ANTIBODY)

=> S (E3) AND (ANTIBODY, ZAQ)
             38 "MASUDA YASUSHI"/IN
         321652 ANTIBODY
         383695 ANTIBODIES
         509547 ANTIBODY
                  (ANTIBODY OR ANTIBODIES)
             15 ZAQ
              0 ANTIBODY, ZAQ
                  (ANTIBODY(W)ZAQ)
L7            0 ("MASUDA YASUSHI"/IN) AND (ANTIBODY, ZAQ)

=> S (E3) AND (ZAQ)
             38 "MASUDA YASUSHI"/IN
             15 ZAQ
L8            6 ("MASUDA YASUSHI"/IN) AND (ZAQ)
```

=> DIS L8 1 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L8 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:371291 CAPLUS
DOCUMENT NUMBER: 142:428780
TITLE: Monoclonal antibodies specific to human ZAQL-2 or ZAQL-1 proteins for diagnosis and treatment of CNS disease, motor neuron disease and endocrine disease
INVENTOR(S): Matsumoto, Hirokazu; Noguchi, Jiro; Masuda, Yasushi
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005037870	A1	20050428	WO 2004-JP15961		20041021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE; EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2543447	A1	20050428	CA 2004-2543447		20041021
JP 2005143504	A	20050609	JP 2004-306963		20041021
EP 1688434	A1	20060809	EP 2004-793073		20041021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
US 2007014799	A1	20070118	US 2006-576066		20060418
PRIORITY APPLN. INFO.:			JP 2003-361639	A	20031022
			WO 2004-JP15961	W	20041021

ABSTRACT:
It is intended to provide a novel antibody useful in developing a remedy, a preventive and a diagnostic for diseases in which human ZAQL-2 (a ligand of orphan receptor ZAQ) participates, a method of quantifying ZAQL-2 by using the antibody, etc. More specifically speaking, it is intended to provide an antibody reacting specifically with human ZAQL-2 or its derivative, a method of quantifying ZAQL-2 by using the antibody, a drug containing the antibody and so on.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L8 2 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L8 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:489508 CAPLUS
DOCUMENT NUMBER: 141:48550
TITLE: Knocking out ZAQ gene in mouse and the use of the mouse as disease model for drug screening
INVENTOR(S): Kasuga, Hisao; Miyashita, Hideaki; Masuda,

Yasushi; Otaki, Tetsuya
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 52 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004166596	A	20040617	JP 2002-336379	20021120

PRIORITY APPLN. INFO.: JP 2002-336379 20021120
ABSTRACT:
This invention provides a process of knocking out ZAQ gene in mouse. The part of ZAQ gene was replaced by lacZ gene and the DNA, cDNA sequence of ZAQ genes were disclosed. The transgenic mouse exhibited a phenotype of instability of fertilized eggs and less development of primary embryo. The transgenic mouse provided in this invention can be used as disease model for drug screening for digestive system diseases, endocrine diseases, gonad disease, cancer, immune disease and nerve system diseases.

=> DIS L8 3 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L8 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:633928 CAPLUS
DOCUMENT NUMBER: 139:175555
TITLE: Drug screening for inhibitors of peptide ligands for G-protein-coupled receptors ZAQ and 15E as angiogenesis inhibitors
INVENTOR(S): Ohtaki, Tetsuya; Masuda, Yasushi; Takatsu, Yoshihiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 308 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066860	A1	20030814	WO 2003-JP1057	20030203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003244347	A1	20030902	AU 2003-244347	20030203
JP 2003292455	A	20031015	JP 2003-25335	20030203
EP 1473365	A1	20041103	EP 2003-737460	20030203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005176632	A1	20050811	US 2005-503554	20050321

PRIORITY APPLN. INFO.: JP 2002-27299 A 20020204

WO 2003-JP1057 W 20030203

ABSTRACT:
Provided are a method and kit for screening compds. inhibiting the activity of novel peptide ligands for two orphan G-protein-coupled receptors ZAQ and 15E. Such compds., antisense nucleic acids or antibodies, are usable as, for example, angiogenesis inhibitors in diagnosis, prevention, and therapy for cancer, polycystic ovary syndrome, ovary overstimulation, etc. The amino acid sequences of those peptides, human, mouse, rat, and bovine ZAQ ligand peptide, snake venom MITI and human and other mammalian homolog (Bv8 peptide), are provided. Endocrine gland-derived vascular endothelial growth factor (EG-VEGF, identical to prokineticin 1) is a novel peptide recently identified as a selective mitogen for endocrine gland endothelial cells. The present study demonstrates that EG-VEGF/prokineticin 1 and a peptide closely related to EG-VEGF, prokineticin 2, are cognate ligands of two orphan G-protein-coupled receptors designated ZAQ (= EG-VEGF/PK-R1) and 15E (= EG-VEGF/PK-R2). EG-VEGF/prokineticin 1 and prokineticin 2 induced a transient increase in intracellular calcium ion concentration ([Ca2+]i) with nanomolar potency in Chinese hamster ovary (CHO) cells expressing EG-VEGF/PK-R1 and -R2 and bind to these cells with high affinity and with different receptor selectivity. EG-VEGF/prokineticins provoke rapid phosphorylation of p44/42 MAP kinase and DNA synthesis in the bovine adrenal capillary endothelial cells (BACE). The mRNAs of both EG-VEGF/PK-R1 and -R2 were expressed in BACE. The identification of the receptors for EG-VEGF/prokineticins may provide a novel mol. basis for the regulation of angiogenesis in endocrine glands.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L8 4 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L8 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:615837 CAPLUS
DOCUMENT NUMBER: 137:164746
TITLE: Peptide ligands for mouse and rat orphan G protein-coupled receptor ZAQ, recombinant expression, and uses for drug screening and therapy
INVENTOR(S): Ohtaki, Tetsuya; Masuda, Yasushi; Takatsu, Yoshihiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062996	A1	20020815	WO 2002-JP837	20020201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002228415	A1	20020819	AU 2002-228415	20020201
JP 2003174888	A	20030624	JP 2002-25879	20020201
EP 1357187	A1	20031029	EP 2002-710463	20020201

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2004072293 A1 20040415 US 2003-470951 20030801
PRIORITY APPLN. INFO.: JP 2001-26798 A 20010202
WO 2002-JP837 W 20020201

ABSTRACT:
Peptide ligands for the mouse and rat orphan G protein-coupled receptor ***ZAQ*** , recombinant expression, and a method and reagent kit for screening drug candidates for prevention and treatment of digestive tract diseases, are disclosed. Antibodies against the peptides, as diagnostic agent for digestive tract diseases, are claimed. Transgenic mammals, rodents, in particular, and embryonic stem cells having the ZAQ peptide ligand genes knocked out by reporter gene insertion, are also claimed. CDNAs for peptide ligands of mouse and rat orphan G protein-coupled receptor ZAQ were cloned and sequenced.

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L8 5 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L8 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:615775 CAPLUS
DOCUMENT NUMBER: 137:165839
TITLE: Novel physiologically active peptide and its use
INVENTOR(S): Ohtaki, Tetsuya; Masuda, Yasushi; Takatsu, Yoshihiro; Watanabe, Takuya; Terao, Yasuko; Shintani, Yasushi; Hinuma, Syuji
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 197 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062944	A2	20020815	WO 2002-JP852	20020201
WO 2002062944	A3	20021003		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002230129	A1	20020819	AU 2002-230129	20020201
JP 2003116582	A	20030422	JP 2002-26090	20020201
EP 1357129	A2	20031029	EP 2002-711281	20020201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004048314	A1	20040311	US 2003-467019	20030801
PRIORITY APPLN. INFO.:			JP 2001-26820 A	20010202
			WO 2002-JP852 W	20020201

ABSTRACT:
A novel physiol. active peptide is provided, which is useful in screening a therapeutic/preventive agent and a diagnostic agent for a digestive tract disease or else. More specifically, a method/kit is provided for screening a

compound or its salt capable of promoting or inhibiting the activity of the novel peptide. The compound or its salt obtained by this screening method, and a drug containing this compound or its salt are also provided. This peptide is useful in, for example, diagnosing, treating and preventing a digestive disease or else. It is also useful as a reagent for screening a compound or its salt capable of promoting or inhibiting the activity of the protein.

=> DIS L8 6 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L8 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:72287 CAPLUS
DOCUMENT NUMBER: 136:97391
TITLE: Peptide ligands for human orphan G protein-coupled receptor ZAQ, recombinant expression, and uses for drug screening and therapy
INVENTOR(S): Ohtaki, Tetsuya; Masuda, Yasushi; Takatsu, Yoshihiro; Watanabe, Takuya; Terao, Yasuko; Shintani, Yasushi; Hinuma, Syuji
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 191 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002006483	A1	20020124	WO 2001-JP6162		20010717
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 200172735	A	20020130	AU 2001-72735		20010717
JP 2002335976	A	20021126	JP 2001-216683		20010717
EP 1302542	A1	20030416	EP 2001-951893		20010717
EP 1302542	B1	20070613			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
AT 364698	T	20070715	AT 2001-951893		20010717
US 2004077535	A1	20040422	US 2003-333192		20030929
US 7045299	B2	20060516			
US 2006088915	A1	20060427	US 2005-304129		20051215
PRIORITY APPLN. INFO.:			JP 2000-217442	A	20000718
			JP 2001-26779	A	20010202
			WO 2001-JP6162	W	20010717
			US 2003-333192	A3	20030929

ABSTRACT:
Peptide ligands for the human orphan G protein-coupled receptor protein ***ZAQ*** , recombinant expression; , and a method kit for screening drug candidates for prevention and treatment of digestive tract diseases, and an antibody against the peptides, are disclosed. Peptide ligands activating ***ZAQ*** were purified from milk and sequenced. Intracellular Ca2+ ion elevation was observed in COS-7 cells expressing ZAQ ligand peptides.

```
REFERENCE COUNT:          25    THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> E NOGUCHI JIRO/IN 25
E1            2     NOGUCHI JINICHI/IN
E2            2     NOGUCHI JINKO/IN
E3           13 --> NOGUCHI JIRO/IN
E4            1     NOGUCHI JOJI/IN
E5           10     NOGUCHI JUICHI/IN
E6           12     NOGUCHI JUJI/IN
E7           12     NOGUCHI JUN/IN
E8           53     NOGUCHI JUNICHI/IN
E9            1     NOGUCHI JUNICHIRO/IN
E10          49     NOGUCHI JUNJI/IN
E11          33     NOGUCHI JUNKO/IN
E12          14     NOGUCHI JUNPEI/IN
E13          27     NOGUCHI JUNZO/IN
E14           2     NOGUCHI KAICHI/IN
E15           1     NOGUCHI KAKUJIRO/IN
E16           1     NOGUCHI KANAME/IN
E17           1     NOGUCHI KANJI/IN
E18           1     NOGUCHI KAORI/IN
E19           9     NOGUCHI KAORU/IN
E20           2     NOGUCHI KASAKU/IN
E21           1     NOGUCHI KASHIO/IN
E22           3     NOGUCHI KATAKI/IN
E23          20     NOGUCHI KATSUHIDE/IN
E24          12     NOGUCHI KATSUHIKO/IN
E25          26     NOGUCHI KATSUHIRO/IN

=> S (E3) AND (ZAQ)
            13 "NOGUCHI JIRO"/IN
            15 ZAQ
L9           1 ("NOGUCHI JIRO"/IN) AND (ZAQ)

=> DIS L9 1 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L9   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2005:371291  CAPLUS
DOCUMENT NUMBER:          142:428780
TITLE:                    Monoclonal antibodies specific to human ZAQL-2 or
                          ZAQL-1 proteins for diagnosis and treatment of CNS
                          disease, motor neuron disease and endocrine disease
INVENTOR(S):              Matsumoto, Hirokazu; Noguchi, Jiro; Masuda,
                          Yasushi
PATENT ASSIGNEE(S):       Takeda Pharmaceutical Company Limited, Japan
SOURCE:                   PCT Int. Appl., 51 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     --------------       ----   --------    --------------------     --------
     WO 2005037870         A1    20050428    WO 2004-JP15961          20041021
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
```

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

CA 2543447	A1	20050428	CA 2004-2543447		20041021
JP 2005143504	A	20050609	JP 2004-306963		20041021
EP 1688434	A1	20060809	EP 2004-793073		20041021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
US 2007014799	A1	20070118	US 2006-576066		20060418
PRIORITY APPLN. INFO.:			JP 2003-361639	A	20031022
			WO 2004-JP15961	W	20041021

ABSTRACT:
It is intended to provide a novel antibody useful in developing a remedy, a preventive and a diagnostic for diseases in which human ZAQL-2 (a ligand of orphan receptor ZAQ) participates, a method of quantifying ZAQL-2 by using the antibody, etc. More specifically speaking, it is intended to provide an antibody reacting specifically with human ZAQL-2 or its derivative, a method of quantifying ZAQL-2 by using the antibody, a drug containing the antibody and so on.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> E MATSUMOTO HIROZAKU/IN 25

E1	16		MATSUMOTO HIROYOSHI/IN
E2	285		MATSUMOTO HIROYUKI/IN
E3	0	-->	MATSUMOTO HIROZAKU/IN
E4	44		MATSUMOTO HIROZO/IN
E5	2		MATSUMOTO HISAFUMI/IN
E6	7		MATSUMOTO HISAHIRO/IN
E7	3		MATSUMOTO HISAKATSU/IN
E8	8		MATSUMOTO HISAMORI/IN
E9	1		MATSUMOTO HISANOBU/IN
E10	4		MATSUMOTO HISANORI/IN
E11	9		MATSUMOTO HISAO/IN
E12	28		MATSUMOTO HISASHI/IN
E13	7		MATSUMOTO HISATO/IN
E14	4		MATSUMOTO HISAYUKI/IN
E15	1		MATSUMOTO HITOSH/IN
E16	197		MATSUMOTO HITOSHI/IN
E17	1		MATSUMOTO HOICHI/IN
E18	1		MATSUMOTO HOSAGP/IN
E19	2		MATSUMOTO HOSHI/IN
E20	2		MATSUMOTO ICHIO/IN
E21	12		MATSUMOTO ICHIRO/IN
E22	2		MATSUMOTO IHEI/IN
E23	3		MATSUMOTO IKKI/IN
E24	2		MATSUMOTO IKU/IN
E25	2		MATSUMOTO IKUHIRO/IN